These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 26958811)

  • 1. A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
    Papadakis E; Robson N; Yeomans A; Bailey S; Laversin S; Beers S; Sayan AE; Ashton-Key M; Schwaiger S; Stuppner H; Troppmair J; Packham G; Cutress R
    Oncotarget; 2016 Apr; 7(14):18851-64. PubMed ID: 26958811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo.
    Han X; Zhang X; Li H; Huang S; Zhang S; Wang F; Shi Y
    Oncotarget; 2015 Nov; 6(36):38912-25. PubMed ID: 26498681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
    Browne BC; Crown J; Venkatesan N; Duffy MJ; Clynes M; Slamon D; O'Donovan N
    Ann Oncol; 2011 Jan; 22(1):68-73. PubMed ID: 20647220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.
    Chakraborty AK; Zerillo C; DiGiovanna MP
    Breast Cancer Res Treat; 2015 Aug; 152(3):533-44. PubMed ID: 26195122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2
    Kar A; Liu B; Gutierrez-Hartmann A
    Anticancer Res; 2017 Dec; 37(12):6583-6591. PubMed ID: 29187433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    Lee JY; Joo HS; Choi HJ; Jin S; Kim HY; Jeong GY; An HW; Park MK; Lee SE; Kim WS; Son T; Min KW; Oh YH; Kong G
    J Natl Cancer Inst; 2019 Jun; 111(6):609-619. PubMed ID: 30265336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
    Sabbaghi M; Gil-Gómez G; Guardia C; Servitja S; Arpí O; García-Alonso S; Menendez S; Arumi-Uria M; Serrano L; Salido M; Muntasell A; Martínez-García M; Zazo S; Chamizo C; González-Alonso P; Madoz-Gúrpide J; Eroles P; Arribas J; Tusquets I; Lluch A; Pandiella A; Rojo F; Rovira A; Albanell J
    Clin Cancer Res; 2017 Nov; 23(22):7006-7019. PubMed ID: 28821558
    [No Abstract]   [Full Text] [Related]  

  • 16. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
    McDermott MSJ; Canonici A; Ivers L; Browne BC; Madden SF; O'Brien NA; Crown J; O'Donovan N
    Int J Oncol; 2017 Jun; 50(6):2221-2228. PubMed ID: 28498399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
    Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.
    Aghazadeh S; Yazdanparast R
    Apoptosis; 2016 Nov; 21(11):1302-1314. PubMed ID: 27651367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.